AI Summary Pioglitazone (Actos) is a once-daily oral tablet that improves insulin sensitivity in adults with type 2 diabetes and is sometimes used in selected patients with MASLD or MASH.
Medically Reviewed.
Pioglitazone (Actos) is a prescription medication approved to improve insulin sensitivity in adults with type 2 diabetes. It belongs to a class of medications called thiazolidinediones (TZDs), which help the body use insulin more effectively. Because insulin resistance is a central driver of MASLD and MASH, some healthcare providers prescribe pioglitazone for selected patients with these conditions to address this underlying metabolic risk factor. By improving insulin sensitivity and helping lower blood glucose, it may help reduce liver fat and improve certain features of MASH in selected patients, though it is not FDA-approved specifically for liver disease. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers pioglitazone's role in MASLD and MASH management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether pioglitazone fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT PIOGLITAZONE TREATMENT
Pioglitazone is a prescription medicine sold under the brand name Actos. It belongs to a class of medications called thiazolidinediones (TZDs), which improve insulin sensitivity in the liver, muscle, and fat tissue and help the body use its own insulin more effectively.
Pioglitazone is approved to improve insulin sensitivity in adults with type 2 diabetes. Because insulin resistance is closely linked to MASLD and MASH, some healthcare providers prescribe pioglitazone for selected patients with these conditions to address this underlying metabolic risk factor, even though it is not a direct liver treatment.
It is typically used as part of a broader, personalised treatment plan that may include dietary changes, physical activity, and regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs) or imaging.
WHO PIOGLITAZONE MAY BE SUITABLE FOR
Eligibility for pioglitazone depends on the medication's approved uses, your diagnosis, and your individual health needs. Your healthcare provider may prescribe pioglitazone if you have type 2 diabetes with insulin resistance, MASLD or MASH associated with metabolic dysfunction, require additional blood sugar control, or if lifestyle modifications alone have not achieved treatment goals.
Your medical history, current health status, liver condition, and any other medications you take all factor into whether pioglitazone is an appropriate option for you.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take pioglitazone. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition, metabolic health, and treatment goals. Your doctor will weigh the potential benefits against any risks — including fluid retention and weight gain — before determining whether pioglitazone fits safely into your broader care plan.
ELIGIBILITY OVERVIEW
Pioglitazone may be considered for adults with the following conditions, risk factors, or treatment goals:
Before recommending pioglitazone, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW PIOGLITAZONE CAN HELP YOUR LIVER
Pioglitazone improves insulin sensitivity in the liver, muscle, and fat tissue, which reduces insulin resistance and helps lower blood glucose levels. It works differently from GLP-1 medications: rather than acting on appetite or digestion, it changes how the body's cells respond to the insulin already circulating.
This action targets a central driver behind MASLD and MASH: insulin resistance. As insulin sensitivity improves, fat tends to build up less in liver cells, and pioglitazone may help improve certain features of MASH in selected patients.
For patients with MASLD or MASH, these metabolic changes can support treatment goals such as better blood sugar control and reduced liver fat accumulation. Pioglitazone is not used on its own — providers pair it with dietary changes, physical activity, and regular monitoring, such as Liver Function Tests (LFTs), to support these outcomes.
LIVER BENEFITS
Insulin resistance is a major contributor to fat buildup in liver cells. By improving how the liver, muscle, and fat tissue respond to insulin, pioglitazone addresses this underlying driver and may help reduce liver fat accumulation.
Insulin resistance is a central metabolic pathway in MASLD and MASH. Pioglitazone helps the body use insulin more effectively, supporting healthier blood sugar regulation throughout the body.
In selected patients, improving insulin sensitivity with pioglitazone may help improve certain features of MASH, such as liver fat and inflammation, though individual results vary and ongoing monitoring is needed.
Pioglitazone provides once-daily oral dosing that helps maintain steadier blood glucose levels over time, supporting the overall metabolic health factors linked to liver disease.
Pioglitazone supports metabolic health by improving insulin sensitivity and blood sugar control, which may help people with MASLD or MASH. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Pioglitazone is supplied as an oral tablet. Take it exactly as prescribed by your healthcare provider.
The typical dose ranges from 15-45 mg once daily, depending on treatment goals and response. Most patients are maintained on 15-30 mg once daily, with 45 mg once daily as the maximum dose if needed. Your healthcare provider determines the right dose and any adjustments based on how you respond.
Take pioglitazone with or without food, at the same time each day.
Pioglitazone is generally used as a long-term therapy to improve insulin sensitivity and maintain blood sugar control. In selected patients with MASLD or MASH, treatment may be continued long term if clinical benefit is achieved and the medication is well tolerated. Do not stop taking it without first talking to your healthcare provider.
Store at room temperature, away from moisture and heat.
Regular monitoring of blood glucose, liver function, body weight, and signs of fluid retention is recommended. For people using pioglitazone to support MASLD or MASH management, providers may also monitor liver health measures, such as Liver Function Tests (LFTs), alongside routine follow-up. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Pioglitazone (Actos) may support people with MASLD and MASH by improving insulin sensitivity in the liver, muscle, and fat tissue — a central metabolic driver of fat buildup and inflammation in the liver. By helping the body respond better to insulin and lowering blood glucose, it may contribute to reduced liver fat and improved features of MASH in selected patients over time. The extent of these benefits varies from person to person, depending on their liver condition, overall metabolic health, treatment plan, and how their body responds to therapy. Pioglitazone is not a stand-alone liver treatment — it works best as part of a broader, personalised care plan that combines the medication with lifestyle changes, such as a liver-healthy diet and regular physical activity, along with ongoing monitoring like Liver Function Tests (LFTs) or imaging.
As with any medication, pioglitazone may cause side effects, including weight gain and fluid retention. Your healthcare provider will assess whether pioglitazone is a suitable option for you and will monitor your treatment response throughout therapy, adjusting the dose or overall care plan as needed to balance potential benefits against any risks.
BENEFITS
Pioglitazone helps the liver, muscle, and fat tissue respond more effectively to insulin, reducing insulin resistance — a key driver of MASLD and MASH.
By improving how the body uses insulin, pioglitazone helps lower and stabilize blood glucose levels for long-term diabetes management.
Improved insulin sensitivity may help reduce the amount of fat stored in the liver, which is a central feature of MASLD and MASH.
Pioglitazone is taken as a tablet once a day, offering a convenient oral option without injections or frequent dosing.
These effects should be discussed with your healthcare provider before starting treatment, and reported promptly if they occur, especially swelling or rapid weight gain, which can signal fluid retention. Your provider will monitor your response throughout therapy and adjust the plan as needed.
SUPPORTING YOUR RESULTS
Lifestyle changes are an important part of a comprehensive treatment plan alongside pioglitazone. Adjustments in nutrition, physical activity, weight management, and monitoring for fluid retention may all play a role in supporting your results.
These habits can support how your body responds to treatment and may help improve outcomes over time.
Areas that may support treatment:
COMMON QUESTIONS
Pioglitazone is not FDA-approved to treat MASLD or MASH. It is approved to improve insulin sensitivity in adults with type 2 diabetes. Because insulin resistance is a key driver of metabolic liver disease, some healthcare providers prescribe pioglitazone off-label for selected patients with MASLD or MASH as part of a broader treatment plan. Whether this approach is appropriate depends on your diagnosis, liver condition, and overall health. Talk with a healthcare professional to determine if pioglitazone fits your individual care plan.
Pioglitazone improves how the liver, muscle, and fat tissue respond to insulin, which may help reduce the amount of fat stored in the liver over time. Because insulin resistance contributes to fat buildup in MASLD and MASH, better insulin sensitivity may support improvement in certain features of these conditions in selected patients. Results vary from person to person, and pioglitazone is not a guaranteed treatment for liver fat. A healthcare professional can help set realistic expectations based on your liver health and metabolic profile.
The most common side effects of pioglitazone include weight gain, fluid retention, swelling of the legs or ankles, headache, and upper respiratory tract infections. Swelling or rapid weight gain can signal fluid retention and should be reported to your healthcare provider promptly. Pioglitazone has also been associated with risks such as heart failure and bladder cancer in some patients, so your provider will review your medical history before prescribing it. Regular monitoring helps catch side effects early and keeps treatment safe.
People with a history of heart failure, bladder cancer, or significant fluid retention may not be good candidates for pioglitazone, since the medication can worsen these conditions. Your healthcare provider will review your medical history, current medications, and liver condition before recommending pioglitazone for MASLD, MASH, or type 2 diabetes. Because eligibility depends on individual health factors, only a qualified healthcare professional can determine whether pioglitazone is safe and appropriate for your specific situation.
Pioglitazone is taken as an oral tablet once daily, with or without food, at the same time each day. The typical dose ranges from 15 to 45 mg, with most patients maintained on 15-30 mg daily and 45 mg as the maximum if needed. Your healthcare provider determines the right starting dose and any adjustments based on your response and treatment goals. Do not change your dose or stop taking pioglitazone without first talking to your healthcare provider.
Yes, pioglitazone is generally used as a long-term therapy to improve insulin sensitivity and maintain blood sugar control. In selected patients with MASLD or MASH, treatment may continue long term if it provides clinical benefit and is well tolerated. Long-term use requires ongoing monitoring of blood glucose, liver function, body weight, and signs of fluid retention. Do not stop taking pioglitazone without first discussing it with your healthcare provider, since stopping abruptly can affect blood sugar control.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
